Geneoscopy, Inc. announced that Exact Sciences has withdrawn its motion for a preliminary injunction tied to two patents (’781 and ’746). The move follows recent setbacks for Exact Sciences at the U.S. Patent Trial and Appeal Board (PTAB), which invalidated all 20 challenged claims of the ’781 patent and initiated review of the ’746 patent.
This decision allows Geneoscopy to continue commercializing ColoSense, its stool-based colorectal cancer screening test, without restriction.
Key Takeaways
Innovation over litigation
Geneoscopy maintained from the start that ColoSense was built on original science, not infringement. CEO Andrew Barnell called the withdrawal a validation of the company’s stance and a win for innovation-driven competition.
Momentum for ColoSense
With the injunction removed, Geneoscopy is free to expand access to its patient-friendly, noninvasive test, which aims to improve early colorectal cancer detection and outcomes.
Shifting patent landscape
The PTAB’s rulings not only strengthen Geneoscopy’s legal position but may also reshape the competitive environment in stool-based CRC screening, historically dominated by Exact Sciences’ Cologuard.